Osteosarcomas of the mandible: Are they different from other tumor sites?

Juliette Thariat, Morbize Julieron, Anne Brouchet, Antoine Italiano, Thomas Schouman, Pierre Yves Marcy, Guillaume Odin, Alexis Lacout, Olivier Dassonville, Isabelle Peyrottes-Birstwisles, Robert Miller, Antoine Thyss, Nicolas Isambert

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Osteosarcomas of the mandible (MOS) affect 1/10. million. persons/year, mostly the young adult. Due to lack of specific data, the treatment of MOS is extrapolated from that of extragnathic OS but varies widely between institutions. Materials and methods: We aimed at providing a focused description of MOS histologies and grades through the English literature, at determining the evidence-based role of chemotherapy, of adjuvant radiation therapy and the potential of reconstructive surgery tailored through modern pre-operative multi-modal imaging. Results: The estimated proportion of high grade MOS was 58%. However, low-grade MOS may be underestimated as they are mostly reported as case reports. The intermediate grade was hardly found in the literature. Estimated weighted-mean proportions of chondroblastic and osteoblastic MOS were 37% and 46%, respectively. Multimodal imaging modalities including MRI has a great potential for accurate pre-operative assessment of tumor extensions into bone and soft tissues. Surgery is the mainstay of treatment and margins the most important factor. The role of neoadjuvant chemotherapy in treating occult systemic metastases and in increasing the probability of clear margins is controversial, as well as the histology-dependent response to chemotherapy. The role of adjuvant radiotherapy (mostly proposed for positive margins) and/or adjuvant chemotherapy is still controversial. Crude survival is around 77% and local control around 67%. Local failure is the main cause of death in MOS compared to extragnathic sites.

Original languageEnglish (US)
Pages (from-to)280-295
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume82
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Osteosarcoma
Adjuvant Chemotherapy
Mandible
Histology
Reconstructive Surgical Procedures
Multimodal Imaging
Literature
Drug Therapy
Adjuvant Radiotherapy
Young Adult
Cause of Death
Neoplasms
Radiotherapy
Neoplasm Metastasis
Bone and Bones
Survival
Therapeutics

Keywords

  • Chemotherapy
  • Head and neck
  • Histology
  • Jaw
  • Mandible
  • Osteogenic sarcoma
  • Osteosarcomas
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Thariat, J., Julieron, M., Brouchet, A., Italiano, A., Schouman, T., Marcy, P. Y., ... Isambert, N. (2012). Osteosarcomas of the mandible: Are they different from other tumor sites? Critical Reviews in Oncology/Hematology, 82(3), 280-295. https://doi.org/10.1016/j.critrevonc.2011.07.001

Osteosarcomas of the mandible : Are they different from other tumor sites? / Thariat, Juliette; Julieron, Morbize; Brouchet, Anne; Italiano, Antoine; Schouman, Thomas; Marcy, Pierre Yves; Odin, Guillaume; Lacout, Alexis; Dassonville, Olivier; Peyrottes-Birstwisles, Isabelle; Miller, Robert; Thyss, Antoine; Isambert, Nicolas.

In: Critical Reviews in Oncology/Hematology, Vol. 82, No. 3, 06.2012, p. 280-295.

Research output: Contribution to journalArticle

Thariat, J, Julieron, M, Brouchet, A, Italiano, A, Schouman, T, Marcy, PY, Odin, G, Lacout, A, Dassonville, O, Peyrottes-Birstwisles, I, Miller, R, Thyss, A & Isambert, N 2012, 'Osteosarcomas of the mandible: Are they different from other tumor sites?', Critical Reviews in Oncology/Hematology, vol. 82, no. 3, pp. 280-295. https://doi.org/10.1016/j.critrevonc.2011.07.001
Thariat, Juliette ; Julieron, Morbize ; Brouchet, Anne ; Italiano, Antoine ; Schouman, Thomas ; Marcy, Pierre Yves ; Odin, Guillaume ; Lacout, Alexis ; Dassonville, Olivier ; Peyrottes-Birstwisles, Isabelle ; Miller, Robert ; Thyss, Antoine ; Isambert, Nicolas. / Osteosarcomas of the mandible : Are they different from other tumor sites?. In: Critical Reviews in Oncology/Hematology. 2012 ; Vol. 82, No. 3. pp. 280-295.
@article{5d853cfbb7ce441880313a1861c1e831,
title = "Osteosarcomas of the mandible: Are they different from other tumor sites?",
abstract = "Background: Osteosarcomas of the mandible (MOS) affect 1/10. million. persons/year, mostly the young adult. Due to lack of specific data, the treatment of MOS is extrapolated from that of extragnathic OS but varies widely between institutions. Materials and methods: We aimed at providing a focused description of MOS histologies and grades through the English literature, at determining the evidence-based role of chemotherapy, of adjuvant radiation therapy and the potential of reconstructive surgery tailored through modern pre-operative multi-modal imaging. Results: The estimated proportion of high grade MOS was 58{\%}. However, low-grade MOS may be underestimated as they are mostly reported as case reports. The intermediate grade was hardly found in the literature. Estimated weighted-mean proportions of chondroblastic and osteoblastic MOS were 37{\%} and 46{\%}, respectively. Multimodal imaging modalities including MRI has a great potential for accurate pre-operative assessment of tumor extensions into bone and soft tissues. Surgery is the mainstay of treatment and margins the most important factor. The role of neoadjuvant chemotherapy in treating occult systemic metastases and in increasing the probability of clear margins is controversial, as well as the histology-dependent response to chemotherapy. The role of adjuvant radiotherapy (mostly proposed for positive margins) and/or adjuvant chemotherapy is still controversial. Crude survival is around 77{\%} and local control around 67{\%}. Local failure is the main cause of death in MOS compared to extragnathic sites.",
keywords = "Chemotherapy, Head and neck, Histology, Jaw, Mandible, Osteogenic sarcoma, Osteosarcomas, Radiotherapy, Surgery",
author = "Juliette Thariat and Morbize Julieron and Anne Brouchet and Antoine Italiano and Thomas Schouman and Marcy, {Pierre Yves} and Guillaume Odin and Alexis Lacout and Olivier Dassonville and Isabelle Peyrottes-Birstwisles and Robert Miller and Antoine Thyss and Nicolas Isambert",
year = "2012",
month = "6",
doi = "10.1016/j.critrevonc.2011.07.001",
language = "English (US)",
volume = "82",
pages = "280--295",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Osteosarcomas of the mandible

T2 - Are they different from other tumor sites?

AU - Thariat, Juliette

AU - Julieron, Morbize

AU - Brouchet, Anne

AU - Italiano, Antoine

AU - Schouman, Thomas

AU - Marcy, Pierre Yves

AU - Odin, Guillaume

AU - Lacout, Alexis

AU - Dassonville, Olivier

AU - Peyrottes-Birstwisles, Isabelle

AU - Miller, Robert

AU - Thyss, Antoine

AU - Isambert, Nicolas

PY - 2012/6

Y1 - 2012/6

N2 - Background: Osteosarcomas of the mandible (MOS) affect 1/10. million. persons/year, mostly the young adult. Due to lack of specific data, the treatment of MOS is extrapolated from that of extragnathic OS but varies widely between institutions. Materials and methods: We aimed at providing a focused description of MOS histologies and grades through the English literature, at determining the evidence-based role of chemotherapy, of adjuvant radiation therapy and the potential of reconstructive surgery tailored through modern pre-operative multi-modal imaging. Results: The estimated proportion of high grade MOS was 58%. However, low-grade MOS may be underestimated as they are mostly reported as case reports. The intermediate grade was hardly found in the literature. Estimated weighted-mean proportions of chondroblastic and osteoblastic MOS were 37% and 46%, respectively. Multimodal imaging modalities including MRI has a great potential for accurate pre-operative assessment of tumor extensions into bone and soft tissues. Surgery is the mainstay of treatment and margins the most important factor. The role of neoadjuvant chemotherapy in treating occult systemic metastases and in increasing the probability of clear margins is controversial, as well as the histology-dependent response to chemotherapy. The role of adjuvant radiotherapy (mostly proposed for positive margins) and/or adjuvant chemotherapy is still controversial. Crude survival is around 77% and local control around 67%. Local failure is the main cause of death in MOS compared to extragnathic sites.

AB - Background: Osteosarcomas of the mandible (MOS) affect 1/10. million. persons/year, mostly the young adult. Due to lack of specific data, the treatment of MOS is extrapolated from that of extragnathic OS but varies widely between institutions. Materials and methods: We aimed at providing a focused description of MOS histologies and grades through the English literature, at determining the evidence-based role of chemotherapy, of adjuvant radiation therapy and the potential of reconstructive surgery tailored through modern pre-operative multi-modal imaging. Results: The estimated proportion of high grade MOS was 58%. However, low-grade MOS may be underestimated as they are mostly reported as case reports. The intermediate grade was hardly found in the literature. Estimated weighted-mean proportions of chondroblastic and osteoblastic MOS were 37% and 46%, respectively. Multimodal imaging modalities including MRI has a great potential for accurate pre-operative assessment of tumor extensions into bone and soft tissues. Surgery is the mainstay of treatment and margins the most important factor. The role of neoadjuvant chemotherapy in treating occult systemic metastases and in increasing the probability of clear margins is controversial, as well as the histology-dependent response to chemotherapy. The role of adjuvant radiotherapy (mostly proposed for positive margins) and/or adjuvant chemotherapy is still controversial. Crude survival is around 77% and local control around 67%. Local failure is the main cause of death in MOS compared to extragnathic sites.

KW - Chemotherapy

KW - Head and neck

KW - Histology

KW - Jaw

KW - Mandible

KW - Osteogenic sarcoma

KW - Osteosarcomas

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84861183550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861183550&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.07.001

DO - 10.1016/j.critrevonc.2011.07.001

M3 - Article

C2 - 21868246

AN - SCOPUS:84861183550

VL - 82

SP - 280

EP - 295

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -